董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rajiv Patni | 男 | Independent Director | 56 | 未披露 | 未持股 | 2025-12-12 |
| Vimal Mehta | 男 | Chief Executive Officer,President and Director | 64 | 111.92万美元 | 未持股 | 2025-12-12 |
| Sandeep Laumas | 男 | Independent Director | 57 | 11.29万美元 | 未持股 | 2025-12-12 |
| David Mack | 男 | Independent Director | 54 | 21.56万美元 | 未持股 | 2025-12-12 |
| Michael Miller | 男 | Independent Director | 68 | 9.04万美元 | 未持股 | 2025-12-12 |
| Michal Votruba | 男 | Independent Director | 59 | 9.04万美元 | 未持股 | 2025-12-12 |
| June Bray | 女 | Independent Director | 72 | 8.54万美元 | 未持股 | 2025-12-12 |
| Rajiv Patni | 男 | Independent Director | 57 | 未披露 | 未持股 | 2025-12-12 |
| Peter Mueller | 男 | Chairman of the Board and Independent Director | 69 | 15.04万美元 | 未持股 | 2025-12-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Javier Rodriguez | 男 | Senior Vice President,Chief Legal Officer and Corporate Secretary | 53 | 101.27万美元 | 未持股 | 2025-12-12 |
| Vimal Mehta | 男 | Chief Executive Officer,President and Director | 64 | 111.92万美元 | 未持股 | 2025-12-12 |
| Richard Steinhart | 男 | Chief Financial Officer and Senior Vice President | 68 | 99.41万美元 | 未持股 | 2025-12-12 |
| Frank Yocca | 男 | Chief Scientific Officer and Senior Vice President | 69 | 21.00万美元 | 未持股 | 2025-12-12 |
董事简历
中英对照 | 中文 | 英文- Rajiv Patni
-
Rajiv Patni，自2025年1月起担任Bioxcel Therapeutics Therapeutics，Inc.的董事。Patni博士自2024年9月起担任柔度生物的首席执行官，柔度生物是一家生物制药开发公司，专注于开拓向肾脏输送的寡核苷酸药物。He previoly曾在Reata制药担任首席研发官，该公司是一家商业阶段公司，直到2023年9月被渤健收购，目前担任Quince Therapeutics，Inc.（纳斯达克：QNCX）的董事会成员。Previoly表示，Patni博士还曾在多家公共、商业阶段的生物制药公司担任首席医疗官——自2020年8月至2023年6月，生物制药公司全球血液疗法、自2020年2月至2020年7月以及自2015年6月至2020年1月，以及Adamas Pharmaceuticals担任首席医疗官，直至被更大的公司收购。在其职业生涯的早期，帕特尼博士曾在辉瑞、罗氏和Actelion担任越来越重要的职务。Patni博士获得了纽约市西奈山伊坎医学院的医学博士学位，这是加速B.S。/M.D。项目的一部分。他在同样位于纽约市的阿尔伯特·爱因斯坦医学院完成了内科住院医师和成人心脏病学研究金，在加入生物制药行业之前，他继续担任主治医师科学家。
Rajiv Patni has served as a director of Bioxcel Therapeutics, Inc. since January 2025. Dr. Patni has served as the Chief Executive Officer of Judo Bio, a biopharmaceutical development company foced on pioneering oligonucleotide medicines delivered to the kidney, since September 2024. He previoly served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial stage company until it was acquired by Biogen in September 2023, and he is currently serving as a board member of Quince Therapeutics, Inc. (Nasdaq: QNCX). Previoly, Dr. Patni also served as Chief Medical Officer at several public, commercial stage biopharmaceutical companies—Global Blood Therapeutics, a biopharmaceutical company, from Augt 2020 to June 2023, Portola Pharmaceuticals from February 2020 to July 2020, and Adamas Pharmaceuticals from June 2015 to January 2020, until their acquisitions by larger companies. Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion. Dr. Patni received his M.D. from the Icahn School of Medicine at Mount Sinai in New York City as part of an accelerated B.S./M.D. program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician scientist before joining the biopharmaceutical indtry. - Rajiv Patni，自2025年1月起担任Bioxcel Therapeutics Therapeutics，Inc.的董事。Patni博士自2024年9月起担任柔度生物的首席执行官，柔度生物是一家生物制药开发公司，专注于开拓向肾脏输送的寡核苷酸药物。He previoly曾在Reata制药担任首席研发官，该公司是一家商业阶段公司，直到2023年9月被渤健收购，目前担任Quince Therapeutics，Inc.（纳斯达克：QNCX）的董事会成员。Previoly表示，Patni博士还曾在多家公共、商业阶段的生物制药公司担任首席医疗官——自2020年8月至2023年6月，生物制药公司全球血液疗法、自2020年2月至2020年7月以及自2015年6月至2020年1月，以及Adamas Pharmaceuticals担任首席医疗官，直至被更大的公司收购。在其职业生涯的早期，帕特尼博士曾在辉瑞、罗氏和Actelion担任越来越重要的职务。Patni博士获得了纽约市西奈山伊坎医学院的医学博士学位，这是加速B.S。/M.D。项目的一部分。他在同样位于纽约市的阿尔伯特·爱因斯坦医学院完成了内科住院医师和成人心脏病学研究金，在加入生物制药行业之前，他继续担任主治医师科学家。
- Rajiv Patni has served as a director of Bioxcel Therapeutics, Inc. since January 2025. Dr. Patni has served as the Chief Executive Officer of Judo Bio, a biopharmaceutical development company foced on pioneering oligonucleotide medicines delivered to the kidney, since September 2024. He previoly served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial stage company until it was acquired by Biogen in September 2023, and he is currently serving as a board member of Quince Therapeutics, Inc. (Nasdaq: QNCX). Previoly, Dr. Patni also served as Chief Medical Officer at several public, commercial stage biopharmaceutical companies—Global Blood Therapeutics, a biopharmaceutical company, from Augt 2020 to June 2023, Portola Pharmaceuticals from February 2020 to July 2020, and Adamas Pharmaceuticals from June 2015 to January 2020, until their acquisitions by larger companies. Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion. Dr. Patni received his M.D. from the Icahn School of Medicine at Mount Sinai in New York City as part of an accelerated B.S./M.D. program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician scientist before joining the biopharmaceutical indtry.
- Vimal Mehta
-
Vimal Mehta自2017年4月起担任董事，自2017年5月起担任我们的首席执行官，总裁兼秘书。他是Bioxcel Corporation的联合创始人，并自2005年以来担任其董事会主席，自2014年9月以来担任其首席执行官。Mehta博士曾担任多个高级科学和业务开发职位，包括2002年至2006年在总部位于伦敦的Inpharmatica Ltd（一家全球预测信息公司）担任业务开发高级副总裁，以及在全球制药和生命科学综合公司Jubilant Life Sciences担任高级副总裁，业务开发，2006年至2007年。此前，Mehta从1996年到2002年担任Curagen Corporation（一家生物技术公司）业务开发经理。他从1989年到1996年在德克萨斯大学西南医学中心放射学系担任多个职位，包括博士后，讲师和助理教授。Mehta博士拥有印度德里大学（University of Delhi）的化学博士学位，并在法国蒙彼利埃大学（University of Montpellier）完成了化学博士后奖学金。在他漫长的职业生涯中，Mehta博士对生物制药和梦百合生态系统有了深刻的了解，并一直积极参与各种全球价值创造倡议，包括公司战略和规划、全球业务发展和公司筹资。
Vimal Mehta co founded the Company and has served as a member of Bioxcel Therapeutics, Inc. Board since April 2017 and as Bioxcel Therapeutics, Inc. Chief Executive Officer and President since May 2017. Dr. Mehta also served as Bioxcel Therapeutics, Inc. Corporate Secretary from May 2017 to February 2021. He is also the co founder and Chief Executive Officer of BioXcel Corporation (now BioXcel LLC). Dr. Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post Doctoral Fellowship in Chemistry at the University of Montpellier, France. During the length of his career, Dr. Mehta has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiatives encompassing corporate strategy and planning, global biness development, and corporate fundraising. - Vimal Mehta自2017年4月起担任董事，自2017年5月起担任我们的首席执行官，总裁兼秘书。他是Bioxcel Corporation的联合创始人，并自2005年以来担任其董事会主席，自2014年9月以来担任其首席执行官。Mehta博士曾担任多个高级科学和业务开发职位，包括2002年至2006年在总部位于伦敦的Inpharmatica Ltd（一家全球预测信息公司）担任业务开发高级副总裁，以及在全球制药和生命科学综合公司Jubilant Life Sciences担任高级副总裁，业务开发，2006年至2007年。此前，Mehta从1996年到2002年担任Curagen Corporation（一家生物技术公司）业务开发经理。他从1989年到1996年在德克萨斯大学西南医学中心放射学系担任多个职位，包括博士后，讲师和助理教授。Mehta博士拥有印度德里大学（University of Delhi）的化学博士学位，并在法国蒙彼利埃大学（University of Montpellier）完成了化学博士后奖学金。在他漫长的职业生涯中，Mehta博士对生物制药和梦百合生态系统有了深刻的了解，并一直积极参与各种全球价值创造倡议，包括公司战略和规划、全球业务发展和公司筹资。
- Vimal Mehta co founded the Company and has served as a member of Bioxcel Therapeutics, Inc. Board since April 2017 and as Bioxcel Therapeutics, Inc. Chief Executive Officer and President since May 2017. Dr. Mehta also served as Bioxcel Therapeutics, Inc. Corporate Secretary from May 2017 to February 2021. He is also the co founder and Chief Executive Officer of BioXcel Corporation (now BioXcel LLC). Dr. Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post Doctoral Fellowship in Chemistry at the University of Montpellier, France. During the length of his career, Dr. Mehta has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiatives encompassing corporate strategy and planning, global biness development, and corporate fundraising.
- Sandeep Laumas
-
Sandeep Laumas自2021年2月起担任我们的首席财务官，自2020年6月起担任我们的首席商务官。他目前自2020年5月起担任9MetersBiopharma，Inc.董事会成员，此前曾于2014年1月至2020年4月担任执行主席，包括2019年2月至2020年4月担任首席执行官。Laumas博士自2017年9月起担任BioxcelTherapeutics，Inc.董事会成员兼审计委员会主席。Laumas博士在康奈尔大学（Cornell University）获得化学学士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位，他在耶鲁大学医学院（Yale University School of Medicine）完成医学实习。
Sandeep Laumas has served as a director of Bioxcel Therapeutics, Inc. since September 2017. Dr. Laumas has served as the Chief Financial Officer and Chief Biness Officer of Instil Bio, Inc. since February 2021 and June 2020, respectively. He began his career at Goldman Sachs & Co. in 1996 in the healthcare investment banking division before transitioning to the healthcare equity research division. He was an analyst at Balyasny Asset Management from 2001 03 and then a Managing Director of North Sound Capital from 2003 07, where he was responsible for the global healthcare investment portfolio. He founded and managed Bearing Circle Capital, an investment partnership, since 2008. Dr. Laumas has served as a member of the board of directors of Bioxcel Therapeutics Inc. since 2017 and a board member of Unicycive Therapeutics Inc. since 2018. He previoly served as a board member of 9 Meters Biopharma, Inc. from 2020 21, its Executive Chairman from 2014 20, including its Chief Executive Officer from 2019 20. Dr. Laumas received his A.B. from Cornell University in 1990, his M.D. from Albany Medical College in 1995, with a research year at the Dana Farber Cancer Institute and completed his medical internship at the Yale University School of Medicine in 1996. - Sandeep Laumas自2021年2月起担任我们的首席财务官，自2020年6月起担任我们的首席商务官。他目前自2020年5月起担任9MetersBiopharma，Inc.董事会成员，此前曾于2014年1月至2020年4月担任执行主席，包括2019年2月至2020年4月担任首席执行官。Laumas博士自2017年9月起担任BioxcelTherapeutics，Inc.董事会成员兼审计委员会主席。Laumas博士在康奈尔大学（Cornell University）获得化学学士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位，他在耶鲁大学医学院（Yale University School of Medicine）完成医学实习。
- Sandeep Laumas has served as a director of Bioxcel Therapeutics, Inc. since September 2017. Dr. Laumas has served as the Chief Financial Officer and Chief Biness Officer of Instil Bio, Inc. since February 2021 and June 2020, respectively. He began his career at Goldman Sachs & Co. in 1996 in the healthcare investment banking division before transitioning to the healthcare equity research division. He was an analyst at Balyasny Asset Management from 2001 03 and then a Managing Director of North Sound Capital from 2003 07, where he was responsible for the global healthcare investment portfolio. He founded and managed Bearing Circle Capital, an investment partnership, since 2008. Dr. Laumas has served as a member of the board of directors of Bioxcel Therapeutics Inc. since 2017 and a board member of Unicycive Therapeutics Inc. since 2018. He previoly served as a board member of 9 Meters Biopharma, Inc. from 2020 21, its Executive Chairman from 2014 20, including its Chief Executive Officer from 2019 20. Dr. Laumas received his A.B. from Cornell University in 1990, his M.D. from Albany Medical College in 1995, with a research year at the Dana Farber Cancer Institute and completed his medical internship at the Yale University School of Medicine in 1996.
- David Mack
-
David Mack自2019年10月起担任我们的首席执行官兼董事会成员。Mack先生是一名律师和投资者，在美国、英国和澳大利亚拥有25年的经验。自2018年1月以来，他一直任职DriveTrain LLC，该公司为公司或房地产提供独立信托服务，例如独立董事，诉讼和清算受托人。马克先生是多家私人公司的董事，此前曾于2017年担任TerraformGlobal，Inc.的董事会成员。2009年至2016年，Mack先生担任Perry Capital（一家位于纽约的对冲基金）的董事总经理。从2000年到2009年，他曾任职Simpson Thacher&Bartlett公司，在那里他曾从事破产和信贷集团的法律实践，专注于为担保贷款人提供建议。2000年之前，他曾任职Linklaters LLP（位于伦敦）和Mallesons Stephen Jaques（位于悉尼）的银行和重组集团。Mack先生在澳大利亚悉尼大学（University of Sydney，Australia）获得文学学士学位和法学学士学位。
David Mack has served as a director of Bioxcel Therapeutics, Inc. since November 2024. Mr. Mack is currently a fiduciary at Drivetrain LLC, a fiduciary services company, a position he has held since 2018.He has previoly served (or serves) on the boards of TerraForm Global, Inc. (NSDQ: GLBL), Speedcast International Limited (ASX: SDA) and Intelsat S.A., among others. He started his career in Sydney as a lawyer with Mallesons Stephen Jaques and then worked for Linklaters LLP in London. In 2000, he moved to the , where he worked at Simpson Thacher & Bartlett, LLP follod by Perry Capital LLC. He has a BA and an LLB (Hons) from the University of Sydney. - David Mack自2019年10月起担任我们的首席执行官兼董事会成员。Mack先生是一名律师和投资者，在美国、英国和澳大利亚拥有25年的经验。自2018年1月以来，他一直任职DriveTrain LLC，该公司为公司或房地产提供独立信托服务，例如独立董事，诉讼和清算受托人。马克先生是多家私人公司的董事，此前曾于2017年担任TerraformGlobal，Inc.的董事会成员。2009年至2016年，Mack先生担任Perry Capital（一家位于纽约的对冲基金）的董事总经理。从2000年到2009年，他曾任职Simpson Thacher&Bartlett公司，在那里他曾从事破产和信贷集团的法律实践，专注于为担保贷款人提供建议。2000年之前，他曾任职Linklaters LLP（位于伦敦）和Mallesons Stephen Jaques（位于悉尼）的银行和重组集团。Mack先生在澳大利亚悉尼大学（University of Sydney，Australia）获得文学学士学位和法学学士学位。
- David Mack has served as a director of Bioxcel Therapeutics, Inc. since November 2024. Mr. Mack is currently a fiduciary at Drivetrain LLC, a fiduciary services company, a position he has held since 2018.He has previoly served (or serves) on the boards of TerraForm Global, Inc. (NSDQ: GLBL), Speedcast International Limited (ASX: SDA) and Intelsat S.A., among others. He started his career in Sydney as a lawyer with Mallesons Stephen Jaques and then worked for Linklaters LLP in London. In 2000, he moved to the , where he worked at Simpson Thacher & Bartlett, LLP follod by Perry Capital LLC. He has a BA and an LLB (Hons) from the University of Sydney.
- Michael Miller
-
Michael Miller，自2022年6月起担任Bioxcel Therapeutics公司董事。他曾担任多家生物制药公司的顾问，包括自2022年6月起的Concarlo Therapeutics和自2022年1月起的里格尔制药公司。在此之前，他于2014年3月至2020年8月担任爵士制药商业执行副总裁。自2018年5月以来，米勒先生一直担任彪马生物技术公司董事会成员，同时也是薪酬委员会成员。米勒先生在旧金山大学获得了学士学位，在旧金山州立大学获得了工商管理硕士学位。
Michael Miller,has served as a director of Bioxcel Therapeutics, Inc. since June 2022. He has served as an advisor to several biopharmaceutical companies, including Concarlo Therapeutics since June 2022 and Rigel Pharmaceuticals, Inc. since January 2022. Prior to that, he served as Executive Vice President, Commercial of Jazz Pharmaceuticals plc from March 2014 to August 2020. Since May 2018, Mr. Miller has served on the Board of Puma Biotechnology Inc., where he also serves on the Compensation Committee. Mr. Miller received his B.S. from the University of San Francisco and his M.B.A. from San Francisco State University. - Michael Miller，自2022年6月起担任Bioxcel Therapeutics公司董事。他曾担任多家生物制药公司的顾问，包括自2022年6月起的Concarlo Therapeutics和自2022年1月起的里格尔制药公司。在此之前，他于2014年3月至2020年8月担任爵士制药商业执行副总裁。自2018年5月以来，米勒先生一直担任彪马生物技术公司董事会成员，同时也是薪酬委员会成员。米勒先生在旧金山大学获得了学士学位，在旧金山州立大学获得了工商管理硕士学位。
- Michael Miller,has served as a director of Bioxcel Therapeutics, Inc. since June 2022. He has served as an advisor to several biopharmaceutical companies, including Concarlo Therapeutics since June 2022 and Rigel Pharmaceuticals, Inc. since January 2022. Prior to that, he served as Executive Vice President, Commercial of Jazz Pharmaceuticals plc from March 2014 to August 2020. Since May 2018, Mr. Miller has served on the Board of Puma Biotechnology Inc., where he also serves on the Compensation Committee. Mr. Miller received his B.S. from the University of San Francisco and his M.B.A. from San Francisco State University.
- Michal Votruba
-
Michal Votruba，自2019年3月起担任Bioxcel Therapeutics, Inc.公司董事。自2013年以来，Votruba博士一直担任Gradus/RSJ生命科学基金的董事，该基金是中欧最大的专项基金，投资组合包括欧洲和美国的公司。沃特鲁巴博士于2015年7月至2019年担任远程行为健康服务公司Mynd Analytics，Inc.的董事，并自2019年起担任Mynd Analytics的继任者Telemynd, Inc.的董事。自2010年以来，他一直担任PrimeCell Therapeutics董事会成员，担任全球业务发展总监，负责监督在中欧运营的最大再生医学公司的扩张。2009年，捷克科学院为布拉格实验医学研究所的第一个成功的私有化项目征求了Votruba博士的专门知识：新创建的协议为捷克共和国未来的私有化项目开创了先例。沃特鲁巴博士于1989年获得布拉格查尔斯大学医学院的医学博士学位。此后不久，他从捷克斯洛伐克移民，并在加拿大和美国发展他的职业生涯。自2005年以来，Votruba博士将他在竞争情报领域的理论和临床经验结合起来，为全球制药行业服务了八年，担任行业分析师，为安进、诺华、礼来、艾尔建、EMD、雪兰诺和赛诺菲等公司的高层领导提供咨询。
Michal Votruba,has served as a director of Bioxcel Therapeutics, Inc. Company since March 2019. Since 2013, Dr. Votruba has been a Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States. Dr. Votruba served as a director of Mynd Analytics, Inc., a telebehavioral health services company, from July 2015 to 2019, and served as a director of Telemynd, Inc., successor to Mynd Analytics, since 2019. Since 2010, he has served as a member of the board of PrimeCell Therapeutics as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe. In 2009, the Czech Academy of Sciences solicited Dr. Votruba's expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague: the newly created protocol established a precedent for future privatization projects in the Czech Republic. Dr. Votruba earned his M.D. from the Medical Faculty of Charles University in Prague in 1989. Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA. Since 2005, Dr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD,Serono and Sanofi. - Michal Votruba，自2019年3月起担任Bioxcel Therapeutics, Inc.公司董事。自2013年以来，Votruba博士一直担任Gradus/RSJ生命科学基金的董事，该基金是中欧最大的专项基金，投资组合包括欧洲和美国的公司。沃特鲁巴博士于2015年7月至2019年担任远程行为健康服务公司Mynd Analytics，Inc.的董事，并自2019年起担任Mynd Analytics的继任者Telemynd, Inc.的董事。自2010年以来，他一直担任PrimeCell Therapeutics董事会成员，担任全球业务发展总监，负责监督在中欧运营的最大再生医学公司的扩张。2009年，捷克科学院为布拉格实验医学研究所的第一个成功的私有化项目征求了Votruba博士的专门知识：新创建的协议为捷克共和国未来的私有化项目开创了先例。沃特鲁巴博士于1989年获得布拉格查尔斯大学医学院的医学博士学位。此后不久，他从捷克斯洛伐克移民，并在加拿大和美国发展他的职业生涯。自2005年以来，Votruba博士将他在竞争情报领域的理论和临床经验结合起来，为全球制药行业服务了八年，担任行业分析师，为安进、诺华、礼来、艾尔建、EMD、雪兰诺和赛诺菲等公司的高层领导提供咨询。
- Michal Votruba,has served as a director of Bioxcel Therapeutics, Inc. Company since March 2019. Since 2013, Dr. Votruba has been a Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States. Dr. Votruba served as a director of Mynd Analytics, Inc., a telebehavioral health services company, from July 2015 to 2019, and served as a director of Telemynd, Inc., successor to Mynd Analytics, since 2019. Since 2010, he has served as a member of the board of PrimeCell Therapeutics as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe. In 2009, the Czech Academy of Sciences solicited Dr. Votruba's expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague: the newly created protocol established a precedent for future privatization projects in the Czech Republic. Dr. Votruba earned his M.D. from the Medical Faculty of Charles University in Prague in 1989. Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA. Since 2005, Dr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD,Serono and Sanofi.
- June Bray
-
琼·布雷，自2021年3月起担任Bioxcel Therapeutics公司董事。她曾于2008年至2020年担任制药公司眼力健制药公司全球监管事务和医学写作高级副总裁，负责所有治疗领域的开发项目和生命周期管理的全球监管战略。从2006年到2008年，布雷女士担任Organon & Co.（在与默沙东合并之前）的监管事务副总裁，领导部门负责开发和销售产品的监管活动。从1980年到2006年，布雷女士在Berlex Laboratories，Inc.担任过各种职务，最近在2003年到2006年担任专门治疗/肿瘤学全球监管事务副总裁。布雷女士自2022年6月起担任Quince Therapeutics，Inc.董事会成员。布雷拥有费尔利·迪金森大学的工商管理硕士学位和罗德岛大学的学士学位。
June Bray,has served as a director of Bioxcel Therapeutics, Inc. since March 2021. She previously served as Senior Vice President, Global Regulatory Affairs and Medical Writing of Allergan, Inc., a pharmaceutical company, from 2008 to 2020, where she was in charge of global regulatory strategies for development projects and lifecycle management for all therapeutic areas. From 2006 to 2008, Ms. Bray was Vice President, Regulatory Affairs at Organon & Co. (prior to its merger with Merck & Co.), where she led departments responsible for regulatory activities for development and marketed products and, from 1980 to 2006, Ms. Bray served in various capacities at Berlex Laboratories, Inc., most recently as Vice President, Global Regulatory Affairs for Specialized Therapeutics/Oncology, a position she held from 2003 to 2006. Ms. Bray has served on the Board of Quince Therapeutics, Inc. since June 2022. Ms. Bray holds an M.B.A. from Fairleigh Dickinson University and a B.S. from the University of Rhode Island. - 琼·布雷，自2021年3月起担任Bioxcel Therapeutics公司董事。她曾于2008年至2020年担任制药公司眼力健制药公司全球监管事务和医学写作高级副总裁，负责所有治疗领域的开发项目和生命周期管理的全球监管战略。从2006年到2008年，布雷女士担任Organon & Co.（在与默沙东合并之前）的监管事务副总裁，领导部门负责开发和销售产品的监管活动。从1980年到2006年，布雷女士在Berlex Laboratories，Inc.担任过各种职务，最近在2003年到2006年担任专门治疗/肿瘤学全球监管事务副总裁。布雷女士自2022年6月起担任Quince Therapeutics，Inc.董事会成员。布雷拥有费尔利·迪金森大学的工商管理硕士学位和罗德岛大学的学士学位。
- June Bray,has served as a director of Bioxcel Therapeutics, Inc. since March 2021. She previously served as Senior Vice President, Global Regulatory Affairs and Medical Writing of Allergan, Inc., a pharmaceutical company, from 2008 to 2020, where she was in charge of global regulatory strategies for development projects and lifecycle management for all therapeutic areas. From 2006 to 2008, Ms. Bray was Vice President, Regulatory Affairs at Organon & Co. (prior to its merger with Merck & Co.), where she led departments responsible for regulatory activities for development and marketed products and, from 1980 to 2006, Ms. Bray served in various capacities at Berlex Laboratories, Inc., most recently as Vice President, Global Regulatory Affairs for Specialized Therapeutics/Oncology, a position she held from 2003 to 2006. Ms. Bray has served on the Board of Quince Therapeutics, Inc. since June 2022. Ms. Bray holds an M.B.A. from Fairleigh Dickinson University and a B.S. from the University of Rhode Island.
- Rajiv Patni
-
Rajiv Patni自2025年1月起担任Bioxcel Therapeutics Therapeutics，Inc.的董事。自2024年9月以来，Patni博士一直担任柔度生物的首席执行官，柔度生物是一家生物制药开发公司，专注于开拓交付肾脏的寡核苷酸药物。He previoly曾在Reata制药担任首席研发官，该公司是一家商业阶段公司，直到2023年9月被渤健收购，目前担任Quince Therapeutics，Inc.（纳斯达克：QNCX）的董事会成员。Previoly表示，Patni博士还曾在多家公共、商业阶段的生物制药公司担任首席医疗官——自2020年8月至2023年6月，生物制药公司全球血液疗法、自2020年2月至2020年7月以及自2015年6月至2020年1月，以及自2015年6月至2020年1月，Adamas Pharmaceuticals均被更大的公司收购。在其职业生涯的早期，帕特尼博士曾在辉瑞、罗氏和Actelion担任越来越多的职务。帕特尼博士在纽约市西奈山伊坎医学院获得医学博士学位，这是加速学士/医学博士项目的一部分。他在同样位于纽约市的阿尔伯特·爱因斯坦医学院完成了内科住院医师和成人心脏病学奖学金，在加入生物制药行业之前，他继续担任主治医师科学家。
Rajiv Patni has served as a director of Bioxcel Therapeutics, Inc. since January 2025. Dr. Patni has served as the Chief Executive Officer of Judo Bio, a biopharmaceutical development company foced on pioneering oligonucleotide medicines delivered to the kidney, since September 2024. He previoly served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial stage company until it was acquired by Biogen in September 2023, and he is currently serving as a board member of Quince Therapeutics, Inc. (Nasdaq: QNCX). Previoly, Dr. Patni also served as Chief Medical Officer at several public, commercial stage biopharmaceutical companies—Global Blood Therapeutics, a biopharmaceutical company, from Augt 2020 to June 2023, Portola Pharmaceuticals from February 2020 to July 2020, and Adamas Pharmaceuticals from June 2015 to January 2020, until their acquisitions by larger cmpanies. Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion. Dr. Patni received his M.D. from the Icahn School of Medicine at Mount Sinai in New York City as part of an accelerated B.S./M.D. program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician scientist before joining the biopharmaceutical indtry. - Rajiv Patni自2025年1月起担任Bioxcel Therapeutics Therapeutics，Inc.的董事。自2024年9月以来，Patni博士一直担任柔度生物的首席执行官，柔度生物是一家生物制药开发公司，专注于开拓交付肾脏的寡核苷酸药物。He previoly曾在Reata制药担任首席研发官，该公司是一家商业阶段公司，直到2023年9月被渤健收购，目前担任Quince Therapeutics，Inc.（纳斯达克：QNCX）的董事会成员。Previoly表示，Patni博士还曾在多家公共、商业阶段的生物制药公司担任首席医疗官——自2020年8月至2023年6月，生物制药公司全球血液疗法、自2020年2月至2020年7月以及自2015年6月至2020年1月，以及自2015年6月至2020年1月，Adamas Pharmaceuticals均被更大的公司收购。在其职业生涯的早期，帕特尼博士曾在辉瑞、罗氏和Actelion担任越来越多的职务。帕特尼博士在纽约市西奈山伊坎医学院获得医学博士学位，这是加速学士/医学博士项目的一部分。他在同样位于纽约市的阿尔伯特·爱因斯坦医学院完成了内科住院医师和成人心脏病学奖学金，在加入生物制药行业之前，他继续担任主治医师科学家。
- Rajiv Patni has served as a director of Bioxcel Therapeutics, Inc. since January 2025. Dr. Patni has served as the Chief Executive Officer of Judo Bio, a biopharmaceutical development company foced on pioneering oligonucleotide medicines delivered to the kidney, since September 2024. He previoly served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial stage company until it was acquired by Biogen in September 2023, and he is currently serving as a board member of Quince Therapeutics, Inc. (Nasdaq: QNCX). Previoly, Dr. Patni also served as Chief Medical Officer at several public, commercial stage biopharmaceutical companies—Global Blood Therapeutics, a biopharmaceutical company, from Augt 2020 to June 2023, Portola Pharmaceuticals from February 2020 to July 2020, and Adamas Pharmaceuticals from June 2015 to January 2020, until their acquisitions by larger cmpanies. Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion. Dr. Patni received his M.D. from the Icahn School of Medicine at Mount Sinai in New York City as part of an accelerated B.S./M.D. program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician scientist before joining the biopharmaceutical indtry.
- Peter Mueller
-
Peter Mueller自2009年5月起担任公司全球研究和发展执行副总裁，2003年7月起担任首席科学家。他是公司药物创新与实现的执行副总裁（2006年2月-2009年 5月）；2003年7月-2006年2月担任药物发现与创新高级副总裁。在加入公司之前，他是Boehringer Ingelheim Pharmaceuticals股份有限公司的研究和开发高级副总裁，负责公司在北美投资的所有候选药物的开发。他负责着在全球基础上的免疫学，炎症性心血管疾病及基因治疗等领域的研究项目。在他在Boehringer Ingelheim的时间里，他监督众多开发候选药物的发现和在基础研究、医学化学和管理等几个职位。他拥有德国乌尔姆爱因斯坦艾伯特大学的毕业生学位和化学博士学位，他也拥有有机化学理论教授职位。他完成了牛津大学量子药理学和Rochester 大学生物物理学的学习。
Peter Mueller has served as Executive Vice President of Global Research and Development of the company since May 2009 and as Chief Scientist since July 2003. He was the Executive Vice President of Drug Innovation and Realization of the company (February 2006 - May 2009). From July 2003 to February 2006, served as Senior Vice President of Drug Discovery and Innovation. Before joining the company, he was the Senior Vice President of Research and Development at Boehringer Ingelheim Pharmaceuticals Inc., responsible for the development of all candidate drugs invested by the company in North America. He is in charge of research projects in the fields of immunology, inflammatory cardiovascular diseases and gene therapy on a global basis. During his time at Boehringer Ingelheim, he oversaw the discovery of numerous drug development candidates and held several positions such as basic research, medical chemistry and management. He holds a graduate degree from Ulm Einstein-Albert University in Germany and a Doctor of Chemistry degree. He also serves as a professor of organic chemistry theory. He completed his studies in quantum pharmacology at the University of Oxford and biophysics at the University of Rochester. - Peter Mueller自2009年5月起担任公司全球研究和发展执行副总裁，2003年7月起担任首席科学家。他是公司药物创新与实现的执行副总裁（2006年2月-2009年 5月）；2003年7月-2006年2月担任药物发现与创新高级副总裁。在加入公司之前，他是Boehringer Ingelheim Pharmaceuticals股份有限公司的研究和开发高级副总裁，负责公司在北美投资的所有候选药物的开发。他负责着在全球基础上的免疫学，炎症性心血管疾病及基因治疗等领域的研究项目。在他在Boehringer Ingelheim的时间里，他监督众多开发候选药物的发现和在基础研究、医学化学和管理等几个职位。他拥有德国乌尔姆爱因斯坦艾伯特大学的毕业生学位和化学博士学位，他也拥有有机化学理论教授职位。他完成了牛津大学量子药理学和Rochester 大学生物物理学的学习。
- Peter Mueller has served as Executive Vice President of Global Research and Development of the company since May 2009 and as Chief Scientist since July 2003. He was the Executive Vice President of Drug Innovation and Realization of the company (February 2006 - May 2009). From July 2003 to February 2006, served as Senior Vice President of Drug Discovery and Innovation. Before joining the company, he was the Senior Vice President of Research and Development at Boehringer Ingelheim Pharmaceuticals Inc., responsible for the development of all candidate drugs invested by the company in North America. He is in charge of research projects in the fields of immunology, inflammatory cardiovascular diseases and gene therapy on a global basis. During his time at Boehringer Ingelheim, he oversaw the discovery of numerous drug development candidates and held several positions such as basic research, medical chemistry and management. He holds a graduate degree from Ulm Einstein-Albert University in Germany and a Doctor of Chemistry degree. He also serves as a professor of organic chemistry theory. He completed his studies in quantum pharmacology at the University of Oxford and biophysics at the University of Rochester.
高管简历
中英对照 | 中文 | 英文- Javier Rodriguez
Javier Rodriguez已经执业超过15年，并在这些年中花费了超过10年担任制药行业的内部法律顾问。 Rodriguez先生于2000年开始其法律职业生涯，担任纽约市Thelen Reid＆Priest律师事务所的诉讼律师。 2004年，他加入了 Berlex Laboratories, Inc.（是Schering AG的子公司）的法律部门，随后在2006年被Bayer AG收购。在Berlex / Bayer期间，Rodriguez先生担任美国诊断成像业务和肿瘤学和专业治疗全球业务部门临床开发功能的公司法律顾问。 2008年，Rodriguez先生加入Reckitt Benckiser LLC，担任医疗保健领域的高级顾问，并帮助成功管理Adams Respiratory Therapeutics, Inc.及其Reckitt Benckiser核心业务超市柜台的整合。随着公司的业务和运营的发展和演变，他在RBP负责越来越重要的法律事务。 2010年，他与Shaun Thaxter一起收购Merck＆Co.，Inc.丁丙诺啡特许经营权的全球前美国市场营销权。在整合了丁丙诺啡业务和成立RBP全球业务之后，Rodriguez先生2011年任命RBP的总法律顾问，随后在Reckitt Benckiser集团的药品业务拆分后于2014年担任Indivior PLC的首席法务官。 Rodriguez先生获得Rutgers University土木工程学士学位和University of Michigan结构工程的硕士学位。他毕业于University of Pennsylvania，获得法学博士学位，并在纽约，新泽西和弗吉尼亚州（法律顾问）执业。
Javier Rodriguez has been practicing law for over 15 years and has spent more than 10 of those years as in-house counsel in the pharmaceuticals industry. Mr. Rodriguez began his legal career in 2000 as a litigation associate at the law firm of Thelen Reid & Priest LLP in New York City. In 2004 he joined the legal department at Berlex Laboratories, Inc., a subsidiary of Schering AG, which was subsequently acquired by Bayer AG in 2006. While at Berlex/Bayer, Mr. Rodriguez served as Corporate Counsel to the clinical development function, the U.S. diagnostic imaging business and the oncology and specialized therapeutics global business units. In 2008 Mr. Rodriguez joined Reckitt Benckiser LLC as Senior Counsel to the healthcare category and helped successfully manage the integration of Adams Respiratory Therapeutics, Inc. and its portfolio of over the counter products into the core Reckitt Benckiser business. He also took on increasing responsibility for the legal affairs of RBP as the business and operations of the company grew and evolved. In 2010 he worked alongside Shaun Thaxter on the acquisition of the global ex-US marketing rights to the buprenorphine franchise from Merck & Co., Inc. Following the integration of the buprenorphine business and establishment of RBP as a global business, Mr. Rodriguez was appointed VP General Counsel of RBP in 2011 and subsequently took on his current role as Chief Legal Officer of Indivior PLC in 2014 following the demerger of the pharmaceuticals business from Reckitt Benckiser Group. Mr. Rodriguez obtained his BS in Civil Engineering from Rutgers University and MSE in Structural Engineering from the University of Michigan. He graduated from the University of Pennsylvania with a JD and is admitted to practice law in New York, New Jersey and Virginia (corporate counsel).- Javier Rodriguez已经执业超过15年，并在这些年中花费了超过10年担任制药行业的内部法律顾问。 Rodriguez先生于2000年开始其法律职业生涯，担任纽约市Thelen Reid＆Priest律师事务所的诉讼律师。 2004年，他加入了 Berlex Laboratories, Inc.（是Schering AG的子公司）的法律部门，随后在2006年被Bayer AG收购。在Berlex / Bayer期间，Rodriguez先生担任美国诊断成像业务和肿瘤学和专业治疗全球业务部门临床开发功能的公司法律顾问。 2008年，Rodriguez先生加入Reckitt Benckiser LLC，担任医疗保健领域的高级顾问，并帮助成功管理Adams Respiratory Therapeutics, Inc.及其Reckitt Benckiser核心业务超市柜台的整合。随着公司的业务和运营的发展和演变，他在RBP负责越来越重要的法律事务。 2010年，他与Shaun Thaxter一起收购Merck＆Co.，Inc.丁丙诺啡特许经营权的全球前美国市场营销权。在整合了丁丙诺啡业务和成立RBP全球业务之后，Rodriguez先生2011年任命RBP的总法律顾问，随后在Reckitt Benckiser集团的药品业务拆分后于2014年担任Indivior PLC的首席法务官。 Rodriguez先生获得Rutgers University土木工程学士学位和University of Michigan结构工程的硕士学位。他毕业于University of Pennsylvania，获得法学博士学位，并在纽约，新泽西和弗吉尼亚州（法律顾问）执业。
- Javier Rodriguez has been practicing law for over 15 years and has spent more than 10 of those years as in-house counsel in the pharmaceuticals industry. Mr. Rodriguez began his legal career in 2000 as a litigation associate at the law firm of Thelen Reid & Priest LLP in New York City. In 2004 he joined the legal department at Berlex Laboratories, Inc., a subsidiary of Schering AG, which was subsequently acquired by Bayer AG in 2006. While at Berlex/Bayer, Mr. Rodriguez served as Corporate Counsel to the clinical development function, the U.S. diagnostic imaging business and the oncology and specialized therapeutics global business units. In 2008 Mr. Rodriguez joined Reckitt Benckiser LLC as Senior Counsel to the healthcare category and helped successfully manage the integration of Adams Respiratory Therapeutics, Inc. and its portfolio of over the counter products into the core Reckitt Benckiser business. He also took on increasing responsibility for the legal affairs of RBP as the business and operations of the company grew and evolved. In 2010 he worked alongside Shaun Thaxter on the acquisition of the global ex-US marketing rights to the buprenorphine franchise from Merck & Co., Inc. Following the integration of the buprenorphine business and establishment of RBP as a global business, Mr. Rodriguez was appointed VP General Counsel of RBP in 2011 and subsequently took on his current role as Chief Legal Officer of Indivior PLC in 2014 following the demerger of the pharmaceuticals business from Reckitt Benckiser Group. Mr. Rodriguez obtained his BS in Civil Engineering from Rutgers University and MSE in Structural Engineering from the University of Michigan. He graduated from the University of Pennsylvania with a JD and is admitted to practice law in New York, New Jersey and Virginia (corporate counsel).
- Vimal Mehta
Vimal Mehta自2017年4月起担任董事，自2017年5月起担任我们的首席执行官，总裁兼秘书。他是Bioxcel Corporation的联合创始人，并自2005年以来担任其董事会主席，自2014年9月以来担任其首席执行官。Mehta博士曾担任多个高级科学和业务开发职位，包括2002年至2006年在总部位于伦敦的Inpharmatica Ltd（一家全球预测信息公司）担任业务开发高级副总裁，以及在全球制药和生命科学综合公司Jubilant Life Sciences担任高级副总裁，业务开发，2006年至2007年。此前，Mehta从1996年到2002年担任Curagen Corporation（一家生物技术公司）业务开发经理。他从1989年到1996年在德克萨斯大学西南医学中心放射学系担任多个职位，包括博士后，讲师和助理教授。Mehta博士拥有印度德里大学（University of Delhi）的化学博士学位，并在法国蒙彼利埃大学（University of Montpellier）完成了化学博士后奖学金。在他漫长的职业生涯中，Mehta博士对生物制药和梦百合生态系统有了深刻的了解，并一直积极参与各种全球价值创造倡议，包括公司战略和规划、全球业务发展和公司筹资。
Vimal Mehta co founded the Company and has served as a member of Bioxcel Therapeutics, Inc. Board since April 2017 and as Bioxcel Therapeutics, Inc. Chief Executive Officer and President since May 2017. Dr. Mehta also served as Bioxcel Therapeutics, Inc. Corporate Secretary from May 2017 to February 2021. He is also the co founder and Chief Executive Officer of BioXcel Corporation (now BioXcel LLC). Dr. Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post Doctoral Fellowship in Chemistry at the University of Montpellier, France. During the length of his career, Dr. Mehta has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiatives encompassing corporate strategy and planning, global biness development, and corporate fundraising.- Vimal Mehta自2017年4月起担任董事，自2017年5月起担任我们的首席执行官，总裁兼秘书。他是Bioxcel Corporation的联合创始人，并自2005年以来担任其董事会主席，自2014年9月以来担任其首席执行官。Mehta博士曾担任多个高级科学和业务开发职位，包括2002年至2006年在总部位于伦敦的Inpharmatica Ltd（一家全球预测信息公司）担任业务开发高级副总裁，以及在全球制药和生命科学综合公司Jubilant Life Sciences担任高级副总裁，业务开发，2006年至2007年。此前，Mehta从1996年到2002年担任Curagen Corporation（一家生物技术公司）业务开发经理。他从1989年到1996年在德克萨斯大学西南医学中心放射学系担任多个职位，包括博士后，讲师和助理教授。Mehta博士拥有印度德里大学（University of Delhi）的化学博士学位，并在法国蒙彼利埃大学（University of Montpellier）完成了化学博士后奖学金。在他漫长的职业生涯中，Mehta博士对生物制药和梦百合生态系统有了深刻的了解，并一直积极参与各种全球价值创造倡议，包括公司战略和规划、全球业务发展和公司筹资。
- Vimal Mehta co founded the Company and has served as a member of Bioxcel Therapeutics, Inc. Board since April 2017 and as Bioxcel Therapeutics, Inc. Chief Executive Officer and President since May 2017. Dr. Mehta also served as Bioxcel Therapeutics, Inc. Corporate Secretary from May 2017 to February 2021. He is also the co founder and Chief Executive Officer of BioXcel Corporation (now BioXcel LLC). Dr. Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post Doctoral Fellowship in Chemistry at the University of Montpellier, France. During the length of his career, Dr. Mehta has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiatives encompassing corporate strategy and planning, global biness development, and corporate fundraising.
- Richard Steinhart
Richard Steinhart自2017年10月起担任我们的首席财务官。2015年10月至2017年6月，他担任Remedy Pharmaceuticals，Inc.的Vice President和首席财务官。Steinhart从2014年1月到2015年9月担任生物技术和医疗设备行业金融和战略顾问。2006年4月至2013年12月，Steinhart先生受聘于MELA Sciences，Inc.，担任其Vice President、财务和首席财务官、财务主管和秘书（2006年4月至2012年4月）。2012年4月至2013年12月，Vice President、财务和首席财务官。Steinhart从1992年5月到加入MELA Sciences，担任Forest Street Capital/SAE Ventures（一家精品投资银行、风险资本和管理咨询公司，专注于梦百合和技术公司）总经理。在Forest Street Capital/SAE Ventures之前，他是Emisphere Technologies，Inc.的Vice President和首席财务官。Steinhart先生的其他经验包括在CW Group，Inc.（一家风险投资公司，专注于医疗技术和生物制药公司）任职七年，他在该公司担任普通合伙人和首席财务官。Steinhart先生是ActiniumPharmaceuticals，Inc.和Atossa Genetics，Inc.的董事会成员，他于2013年11月担任该职位，并于2014年3月开始任职。Steinhart先生在Actinium Pharmaceuticals担任审计委员会主席，在那里他还担任薪酬和公司治理委员会成员。Steinhart先生担任Atossa Genetics审计委员会的主席，并且是其薪酬委员会的成员。他持有佩斯大学（Pace University）的B.B.A.和M.B.A.学位，是一名非活跃注册会计师。
Richard Steinhart has served as Bioxcel Therapeutics, Inc. Senior Vice President and Chief Financial Officer since March 2018. From October 2017 to March 2018, Mr. Steinhart served as Bioxcel Therapeutics, Inc. Vice President and Chief Financial Officer. From October 2015 to June 2017, he was Vice President and CFO at Remedy Pharmaceuticals, Inc. From January 2014 to September 2015, Mr. Steinhart worked as a financial and strategic consultant to the biotechnology and medical device indtries. From April 2006 through December 2013, Mr. Steinhart was employed by MELA Sciences, Inc., as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary from April 2006 to April 2012 and as Sr. Vice President, Finance and Chief Financial Officer from April 2012 to December 2013. From May 1992 until joining MELA Sciences, Mr. Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm foced on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart's other experience includes seven years at CW Group, Inc., a venture capital firm foced on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Mr. Steinhart is a member of the board of directors of Actinium Pharmaceuticals, Inc., a position he assumed in November 2013, and Atossa Genetics, Inc., where he began his service in March 2014. Mr. Steinhart serves as the Chairman of the Audit Committee at Actinium Pharmaceuticals, where he also sits on the Corporate Governance Committees. Mr. Steinhart serves as the Chairman of Atossa Genetics Audit Committee and is a member of its Audit Committee and Compensation Committee. He holds B.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant (inactive).- Richard Steinhart自2017年10月起担任我们的首席财务官。2015年10月至2017年6月，他担任Remedy Pharmaceuticals，Inc.的Vice President和首席财务官。Steinhart从2014年1月到2015年9月担任生物技术和医疗设备行业金融和战略顾问。2006年4月至2013年12月，Steinhart先生受聘于MELA Sciences，Inc.，担任其Vice President、财务和首席财务官、财务主管和秘书（2006年4月至2012年4月）。2012年4月至2013年12月，Vice President、财务和首席财务官。Steinhart从1992年5月到加入MELA Sciences，担任Forest Street Capital/SAE Ventures（一家精品投资银行、风险资本和管理咨询公司，专注于梦百合和技术公司）总经理。在Forest Street Capital/SAE Ventures之前，他是Emisphere Technologies，Inc.的Vice President和首席财务官。Steinhart先生的其他经验包括在CW Group，Inc.（一家风险投资公司，专注于医疗技术和生物制药公司）任职七年，他在该公司担任普通合伙人和首席财务官。Steinhart先生是ActiniumPharmaceuticals，Inc.和Atossa Genetics，Inc.的董事会成员，他于2013年11月担任该职位，并于2014年3月开始任职。Steinhart先生在Actinium Pharmaceuticals担任审计委员会主席，在那里他还担任薪酬和公司治理委员会成员。Steinhart先生担任Atossa Genetics审计委员会的主席，并且是其薪酬委员会的成员。他持有佩斯大学（Pace University）的B.B.A.和M.B.A.学位，是一名非活跃注册会计师。
- Richard Steinhart has served as Bioxcel Therapeutics, Inc. Senior Vice President and Chief Financial Officer since March 2018. From October 2017 to March 2018, Mr. Steinhart served as Bioxcel Therapeutics, Inc. Vice President and Chief Financial Officer. From October 2015 to June 2017, he was Vice President and CFO at Remedy Pharmaceuticals, Inc. From January 2014 to September 2015, Mr. Steinhart worked as a financial and strategic consultant to the biotechnology and medical device indtries. From April 2006 through December 2013, Mr. Steinhart was employed by MELA Sciences, Inc., as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary from April 2006 to April 2012 and as Sr. Vice President, Finance and Chief Financial Officer from April 2012 to December 2013. From May 1992 until joining MELA Sciences, Mr. Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm foced on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart's other experience includes seven years at CW Group, Inc., a venture capital firm foced on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Mr. Steinhart is a member of the board of directors of Actinium Pharmaceuticals, Inc., a position he assumed in November 2013, and Atossa Genetics, Inc., where he began his service in March 2014. Mr. Steinhart serves as the Chairman of the Audit Committee at Actinium Pharmaceuticals, where he also sits on the Corporate Governance Committees. Mr. Steinhart serves as the Chairman of Atossa Genetics Audit Committee and is a member of its Audit Committee and Compensation Committee. He holds B.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant (inactive).
- Frank Yocca
Frank Yocca自2017年6月起担任我们的首席科学官。2015年4月至2017年4月，他高级副总裁，Bioxcel的CNS研发。从2005年到2015年，约卡博士在AstraZeneca PLC担任多个领导职务，包括Vice President、战略和外部化、神经科学虚拟创新医学部门IMED2011-2015年Vice President和战略部门负责人、CNS和疼痛创新医学部门IMED2010-2011年以及Vice President和负责人，CNS疼痛发现2005年至2010年。此前，他曾担任Bristol Myers Squibb Pharmaceutical Research Institute的执行董事（从1984年到2004年），在那里他曾同时担任神经科学临床集团的早期和后期临床开发研究的领导职务。此前，他曾担任神经科学发现执行董事（从1997年到2003年），在那里他曾担任公司战略计划的开发和实施的合作者，以及神经科学生物部发现精神病学和阿尔茨海默氏症临床候选人的领导人。从1999年到2002年，他是Abilify产品开发和商业化团队的核心成员，从1984年到2001年，他是早期和晚期发现和开发团队的核心成员。Yocca博士拥有曼哈顿学院（Manhattan College）的生物化学学士学位和圣约翰大学（St.John’s University）的药理学硕士学位和神经药理学博士学位。
Frank Yocca,has served as Bioxcel Therapeutics, Inc. Senior Vice President and Chief Scientific Officer since March 2018. From June 2017 to March 2018, Dr. Yocca served as Bioxcel Therapeutics, Inc. Vice President and Chief Scientific Officer. From April 2015 to April 2017, he was Senior Vice President, CNS R&D of BioXcel. From 2005 to 2015, Dr. Yocca held multiple leadership roles at AstraZeneca plc, including Vice President, Strategy and Externalization, Neuroscience Virtual Innovative Medicine Unit (iMed) (2011-2015), Vice President and Head, Strategy Unit, CNS and Pain Innovative Medicine Unit (iMed) (2010 to 2011) and Vice President and Head, CNS Pain Discovery (2005 to 2010). Prior to this, he was Executive Director at the Bristol Myers Squibb Pharmaceutical Research Institute from 1984 to 2004 where he served concurrent leadership responsibilities within the Neuroscience Clinical Group for Early and Late Clinical Development Studies. Prior to this, Dr. Yocca served as Executive Director, Neuroscience Discovery from 1997 to 2003, where he was a collaborator in the development and implementation of corporate strategic plans and leader for the Neuroscience Biology Department in the discovery of psychiatry and Alzheimer's clinical candidates. He was a core member of the Abilify Product Development and Commercialization Team from 1999 to 2002 and a core member of the Early and Late Discovery and Development Teams from 1984 to 2001. Dr. Yocca holds a B.S. in biochemistry from Manhattan College and an M.S. in pharmacology and a Ph.D. in neuropharmacology from St. John's University.- Frank Yocca自2017年6月起担任我们的首席科学官。2015年4月至2017年4月，他高级副总裁，Bioxcel的CNS研发。从2005年到2015年，约卡博士在AstraZeneca PLC担任多个领导职务，包括Vice President、战略和外部化、神经科学虚拟创新医学部门IMED2011-2015年Vice President和战略部门负责人、CNS和疼痛创新医学部门IMED2010-2011年以及Vice President和负责人，CNS疼痛发现2005年至2010年。此前，他曾担任Bristol Myers Squibb Pharmaceutical Research Institute的执行董事（从1984年到2004年），在那里他曾同时担任神经科学临床集团的早期和后期临床开发研究的领导职务。此前，他曾担任神经科学发现执行董事（从1997年到2003年），在那里他曾担任公司战略计划的开发和实施的合作者，以及神经科学生物部发现精神病学和阿尔茨海默氏症临床候选人的领导人。从1999年到2002年，他是Abilify产品开发和商业化团队的核心成员，从1984年到2001年，他是早期和晚期发现和开发团队的核心成员。Yocca博士拥有曼哈顿学院（Manhattan College）的生物化学学士学位和圣约翰大学（St.John’s University）的药理学硕士学位和神经药理学博士学位。
- Frank Yocca,has served as Bioxcel Therapeutics, Inc. Senior Vice President and Chief Scientific Officer since March 2018. From June 2017 to March 2018, Dr. Yocca served as Bioxcel Therapeutics, Inc. Vice President and Chief Scientific Officer. From April 2015 to April 2017, he was Senior Vice President, CNS R&D of BioXcel. From 2005 to 2015, Dr. Yocca held multiple leadership roles at AstraZeneca plc, including Vice President, Strategy and Externalization, Neuroscience Virtual Innovative Medicine Unit (iMed) (2011-2015), Vice President and Head, Strategy Unit, CNS and Pain Innovative Medicine Unit (iMed) (2010 to 2011) and Vice President and Head, CNS Pain Discovery (2005 to 2010). Prior to this, he was Executive Director at the Bristol Myers Squibb Pharmaceutical Research Institute from 1984 to 2004 where he served concurrent leadership responsibilities within the Neuroscience Clinical Group for Early and Late Clinical Development Studies. Prior to this, Dr. Yocca served as Executive Director, Neuroscience Discovery from 1997 to 2003, where he was a collaborator in the development and implementation of corporate strategic plans and leader for the Neuroscience Biology Department in the discovery of psychiatry and Alzheimer's clinical candidates. He was a core member of the Abilify Product Development and Commercialization Team from 1999 to 2002 and a core member of the Early and Late Discovery and Development Teams from 1984 to 2001. Dr. Yocca holds a B.S. in biochemistry from Manhattan College and an M.S. in pharmacology and a Ph.D. in neuropharmacology from St. John's University.